bluebird bio, Inc. (BLUE) |
|
4.45 -0.15 (-3.26%)
|
03-22 12:26 |
|
Open: |
4.57 |
Pre. Close: |
4.6 |
|
High:
|
4.57 |
Low:
|
4.41 |
|
Volume:
|
743,265 |
Market Cap:
|
458(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 12:15:04 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 6.07 One year: 6.94 |
| Support: |
Support1: 4 Support2: 3.32 |
| Resistance: |
Resistance1: 5.2 Resistance2: 5.94 |
| Pivot: |
4.72 |
| Moving Average: |
MA(5): 4.52 MA(20): 4.83
MA(100): 6.53 MA(250): 5.59 |
| MACD: |
MACD(12,26): -0.4  Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 39.1 %D(3): 40.6 |
| RSI: |
RSI(14): 34.6 |
| 52-week: |
High: 8.57 Low: 2.86 |
| Average Vol(K): |
3-Month: 3,782 (K) 10-Days: 5,446 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BLUE ] has closed above bottom band by 21.0%. Bollinger Bands are 40% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.69 - 4.72 |
4.72 - 4.74 |
|
Low:
|
4.4 - 4.44 |
4.44 - 4.48 |
|
Close:
|
4.54 - 4.6 |
4.6 - 4.66 |
|
Company Description |
|
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Wed, 22 Mar 2023
bluebird bio (BLUE) Scheduled to Post Quarterly Earnings on ... - MarketBeat
Tue, 21 Mar 2023
BNSF hires Graves' former chief - POLITICO - POLITICO
Fri, 17 Mar 2023
Sarepta slides as surprise FDA panel meet adds uncertainty for ... - Nasdaq
Mon, 13 Mar 2023
Should You Buy bluebird bio Inc (BLUE) Stock After it Is Lower By 5.31% in a Week? - InvestorsObserver
Mon, 13 Mar 2023
With 2.5% one-year returns, institutional owners may ignore bluebird bio, Inc.'s (NASDAQ:BLUE) 15% stock price decline - Simply Wall St
Sat, 11 Mar 2023
Verition Fund Management LLC has invested $233,000 in bluebird ... - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
103 (M) |
|
% Held by Insiders
|
8.218e+007 (%) |
|
% Held by Institutions
|
1 (%) |
|
Shares Short
|
17,290 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.4638e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-8 |
|
Return on Assets (ttm)
|
526.2 |
|
Return on Equity (ttm)
|
-29.5 |
|
Qtrly Rev. Growth
|
5.14e+006 |
|
Gross Profit (p.s.)
|
-93.94 |
|
Sales Per Share
|
-84.62 |
|
EBITDA (p.s.)
|
-3.54687e+008 |
|
Qtrly Earnings Growth
|
-5.6 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-436 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.06 |
|
Price to Cash Flow
|
2.28 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.828e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
